Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R.
Ribas A, et al. Among authors: gonzalez r.
J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236.
J Transl Med. 2012.
PMID: 23171508
Free PMC article.
Clinical Trial.